Clynav
Salmon pancreas disease vaccine (recombinant DNA plasmid)
Table of contents
Overview
Clynav is a veterinary vaccine used to protect Atlantic salmon against pancreas disease caused by salmonid alphavirus subtype 3 (SAV3). Pancreas disease in Atlantic salmon can reduce weight gain, leads to damage of the heart, pancreas and skeletal muscle, and may cause death.
The active substance in Clynav is a DNA plasmid (a small piece of DNA) containing the genetic code for making proteins found in salmon pancreas disease virus (SPDV).
Authorisation details
Product details | |
---|---|
Name |
Clynav
|
Agency product number |
EMEA/V/C/002390
|
Active substance |
pUK-SPDV-poly2#1 DNA plasmid coding for salmon pancreas disease virus proteins
|
International non-proprietary name (INN) or common name |
Salmon pancreas disease vaccine (recombinant DNA plasmid)
|
Species |
Atlantic salmon
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
QI10AX
|
Publication details | |
---|---|
Marketing-authorisation holder |
Elanco GmbH
|
Revision |
5
|
Date of issue of marketing authorisation valid throughout the European Union |
26/06/2017
|
Contact address |
Heinz-Lohmann-Str 4 |
Product information
27/03/2020 Clynav - EMEA/V/C/002390 - II/0010
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Immunologicals for Atlantic salmon
Therapeutic indication
For the active immunisation of Atlantic salmon to reduce impaired daily weight gain, and reduce mortality, and cardiac, pancreatic and skeletal muscle lesions caused by pancreas disease following infection with salmonid alphavirus subtype 3 (SAV3).